<DOC>
	<DOCNO>NCT00670592</DOCNO>
	<brief_summary>This study evaluate high tolerate dose , safety activity HCD122 adults non-Hodgkin 's Hodgkin 's lymphoma receive least two prior therapy .</brief_summary>
	<brief_title>Study HCD122 Adults With Non-Hodgkin 's Hodgkin 's Lymphoma Who Have Progressed After Least Two Prior Therapies</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<criteria>Inclusion criterion : Patients may include study meet follow criterion : Patients must confirm diagnosis HL NHL ( follicular , marginal zone / MALT , diffuse large Bcell , mantle cell ) per REAL/WHO classification Patients must progress least 2 prior therapy ( autologous stem cell transplantation consider 1 therapy ) Patients must â‰¥ 18 year Patients must life expectancy &gt; 3 month Patient must adequate laboratory result Patients must WHO Performance Status grade 0 , 1 , 2 Patients must least one site measurable disease Patients must discontinue previous monoclonal antibody radioimmunotherapy , must recover fully side effect treatment prior begin study treatment . Patients must willing able sign inform consent form comply study protocol Exclusion criterion : Patients exclude study meet follow criterion : Patients treat antiCD40 antibody Patients receive prior allogeneic stem cell transplant Patients prior anaphylactic severe infusion reaction patient unable tolerate human immunoglobulin monoclonal antibody administration Patients history clinical evidence central nervous system , meningeal , epidural disease include brain metastasis Women childbearing potential ( WCBP ) pregnant breast feeding . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>HCD122</keyword>
	<keyword>CD40</keyword>
	<keyword>NHL</keyword>
	<keyword>HL</keyword>
</DOC>